SCHEMBL931937

SCHEMBL931937

N[C@@H]1CN[C@H](C(=O)O)C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8510514 1.00
SCHEMBL932832 1.00
SCHEMBL2728000 1.00
SCHEMBL610339 1.00
SCHEMBL610338 1.00
SCHEMBL7889338 1.00
SCHEMBL7889335 1.00
SCHEMBL8513431 1.00
SCHEMBL10098486 0.81
SCHEMBL10098445 0.81

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 338 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10017481-B2 Conformationally constrained, fully synthetic macrocyclic compounds POLYPHOR AG (CH) 2018-07-10 US claimed
US-9725499-B2 Self-assembling collagen-like polypeptide sequences for applications and uses related thereto EMORY UNIVERSITY (US) 2017-08-08 US claimed
US-9695191-B2 Conformationally constrained, fully synthetic macrocyclic compounds POLYPHOR AG (CH) 2017-07-04 US claimed
US-9512139-B2 Conformationally constrained, fully synthetic macrocyclic compounds POLYPHOR AG (CH) 2016-12-06 US claimed
US-20150252096-A1 SELF-ASSEMBLING COLLAGEN-LIKE POLYPEPTIDE SEQUENCES FOR APPLICATIONS AND USES RELATED THERETO NATIONAL SCIENCE FOUNDATION 2015-09-10 US claimed
US-20150051183-A1 CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS POLYPHOR AG (CH) 2015-02-19 US claimed
US-20140112976-A1 Cyclic Peptides with an Anti-Neoplasic and Anti-Angiogenic Activity CENTRO DE INGENIERIA GENETICA BIOTECNOLOGIA (CU) 2014-04-24 US claimed
EP-2690107-A2 CYCLIC PEPTIDES WITH AN ANTI-NEOPLASIC AND ANTI-ANGIOGENIC ACTIVITY Centro De Ingenieria Genetica Y Biotecnologia (CU) 2014-01-29 EP claimed
US-20120270881-A1 CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS POLYPHOR AG (CH) 2012-10-25 US claimed
US-20120202821-A1 CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS POLYPHOR AG (CH) 2012-08-09 US claimed
US-20110008414-A9 METHOD FOR SYNTHESIZING CONFORMATIONALLY CONSTRAINED PEPTIDES, PEPTIDOMIMETICS AND THE USE THEREOF AS SYNTHETIC VACCINES MYMETICS CORPORATION (US) 2011-01-13 US claimed
US-20090324707-A1 METHOD FOR SYNTHESIZING CONFORMATIONALLY CONSTRAINED PEPTIDES, PEPTIDOMIMETICS AND THE USE THEREOF AS SYNTHETIC VACCINES MYMETICS CORPORATION (US) 2009-12-31 US claimed
US-20060258564-A1 Method for synthesizing conformationally constrained peptides, peptidomimetics and the use thereof as synthetic vaccines MYMETICS CORPORATION 2006-11-16 US claimed
WO-2005116055-A1 PEPTIDES, ANTIBODIES AND COMPOSITIONS CONTAINING SAME USEFUL FOR TREATING HIV VIRUS INFECTION YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) 2005-12-08 WO claimed
EP-1484336-A1 Methods for synthesizing conformationally constrained peptides, peptidometics and the use thereof as synthetic vaccines Pevion Biotech Ltd. (CH) 2004-12-08 EP claimed
US-20260144888-A1 USE OF A LIQUID AQUEOUS COMPOSITION FOR SOLUBILIZATION AND STABILIZATION OF AN ANTIBODY-DRUG CONJUGATE PIERRE FABRE MEDICAMENT (FR) 2026-05-28 US disclosed
US-20260139301-A1 CATALYTIC DE-CROSSLINKING OF SAMPLES FOR IN SITU ANALYSIS 10X GENOMICS INC (US) 2026-05-21 US disclosed
WO-2005116055-A1 PEPTIDES, ANTIBODIES AND COMPOSITIONS CONTAINING SAME USEFUL FOR TREATING HIV VIRUS INFECTION YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) 2005-12-08 WO disclosed
WO-2004106366-A1 METHODS FOR SYNTHESIZING CONFORMATIONALLY CONSTRAINED PEPTIDES, PEPTIDOMETICS AND THE USE THEREOF AS SYNTHETIC VACCINES PEVION BIOTECH LTD. (CH) 2004-12-09 WO disclosed
EP-1484336-A1 Methods for synthesizing conformationally constrained peptides, peptidometics and the use thereof as synthetic vaccines Pevion Biotech Ltd. (CH) 2004-12-08 EP disclosed